| Year |
Citation |
Score |
| 2020 |
Weidhaas JB. Identifying MicroRNA Pathway Variants as Biomarkers of Patient Selection for Immune Therapy. Methods in Molecular Biology (Clifton, N.J.). 2055: 203-212. PMID 31502153 DOI: 10.1007/978-1-4939-9773-2_9 |
0.367 |
|
| 2019 |
Jung SY, Malhotra P, Nguyen KC, Salzman D, Qi Y, Pak EH, King J, Vlashi E, Ann D, Weidhaas JB. The KRAS-variant and its impact on normal breast epithelial cell biology. Cell Death and Differentiation. PMID 30932013 DOI: 10.1038/S41418-019-0320-Y |
0.802 |
|
| 2019 |
Malhotra P, Read GH, Weidhaas JB. Breast Cancer and miR-SNPs: The Importance of miR Germ-Line Genetics. Non-Coding Rna. 5. PMID 30897768 DOI: 10.3390/ncrna5010027 |
0.432 |
|
| 2019 |
Yuan Y, Weidhaas JB. Functional microRNA binding site variants. Molecular Oncology. 13: 4-8. PMID 30536617 DOI: 10.1002/1878-0261.12421 |
0.312 |
|
| 2019 |
Weidhaas JB, Scheffler AW, Salzman D, Kalbasi A, Wilenius K, Rietdorf E, Heilig M, Pitka M, Desler C, Ruan D, Ribas A, Drakaki A, Scholz MC, Telesca D. A germline microRNA-based biomarker signature of immune-associated toxicity to anti-PD1/PDL1 therapy. Journal of Clinical Oncology. 37: 96-96. DOI: 10.1200/Jco.2019.37.8_Suppl.96 |
0.74 |
|
| 2018 |
Hui P, Gysler SM, Uduman M, Togun TA, Prado DE, Richter CE, Nallur S, Schwartz PE, Rutherford TJ, Santin AD, Weidhaas JB, Ratner ES. MicroRNA Signatures Discriminate Between Uterine and Ovarian Serous Carcinomas. Human Pathology. PMID 29518404 DOI: 10.1016/j.humpath.2018.02.019 |
0.321 |
|
| 2018 |
Weidhaas JB, Wilenius K, Scheffler AW, Higa J, Telesca D, Scholz MC. A microRNA-based signature predicting immune-related toxicity (iRAEs) to pembrolizumab in prostate cancer patients. Journal of Clinical Oncology. 36: 269-269. DOI: 10.1200/Jco.2018.36.6_Suppl.269 |
0.329 |
|
| 2017 |
Mehta AK, Hua K, Whipple W, Nguyen MT, Liu CT, Haybaeck J, Weidhaas J, Settleman J, Singh A. Regulation of autophagy, NF-κB signaling, and cell viability by miR-124 in KRAS mutant mesenchymal-like NSCLC cells. Science Signaling. 10. PMID 28900044 DOI: 10.1126/scisignal.aam6291 |
0.342 |
|
| 2017 |
McVeigh TP, Mulligan RJ, McVeigh UM, Owens PW, Miller N, Bell M, Sebag F, Guerin C, Quill D, Weidhaas JB, Kerin M, Lowery AJ. Investigating the association of rs2910164 with cancer in Irish patients. Endocrine Connections. PMID 28899898 DOI: 10.1530/EC-17-0196 |
0.317 |
|
| 2017 |
Weidhaas JB, Telesca D, Kalbasi A, Salzman D, Ribas A. Germ-line biomarkers disrupting microRNA regulatory pathways to predict toxicity and response to anti-PD-1 and anti-PD-L1 therapies. Journal of Clinical Oncology. 35: 3040-3040. DOI: 10.1200/Jco.2017.35.15_Suppl.3040 |
0.761 |
|
| 2016 |
Gautheret D, Taube JH, Mani SA, Santulli G, Cuerda-Gil D, Slotkin RK, Zhang B, Wang Y, Salzman DW, Weidhaas JB. Erratum: The Non-Coding RNA Journal Club: Highlights on Recent Papers-4. Non-Coding RNA 2016, 2, 9. Non-Coding Rna. 2. PMID 29657269 DOI: 10.3390/Ncrna2040010 |
0.697 |
|
| 2016 |
Gautheret D, Taube JH, Mani SA, Santulli G, Cuerda-Gil D, Slotkin RK, Zhang B, Wang Y, Salzman DW, Weidhaas JB. The Non-Coding RNA Journal Club: Highlights on Recent Papers-4. Non-Coding Rna. 2. PMID 29657267 DOI: 10.3390/Ncrna2030009 |
0.698 |
|
| 2016 |
Nemec AA, Bush KB, Towle-Weicksel JB, Taylor BF, Schulz V, Weidhaas J, Tuck DP, Sweasy JB. Estrogen Drives Cellular Transformation and Mutagenesis in Cells Expressing the Breast Cancer-associated R438W DNA Polymerase Lambda Protein. Molecular Cancer Research : McR. PMID 27621267 DOI: 10.1158/1541-7786.Mcr-16-0209 |
0.301 |
|
| 2016 |
Metheetrairut C, Adams BD, Nallur S, Weidhaas JB, Slack FJ. cel-mir-237 and its homologue, hsa-miR-125b, modulate the cellular response to ionizing radiation. Oncogene. PMID 27321180 DOI: 10.1038/Onc.2016.222 |
0.541 |
|
| 2016 |
Salzman DW, Nakamura K, Nallur S, Dookwah MT, Metheetrairut C, Slack FJ, Weidhaas JB. miR-34 activity is modulated through 5'-end phosphorylation in response to DNA damage. Nature Communications. 7: 10954. PMID 26996824 DOI: 10.1038/Ncomms10954 |
0.77 |
|
| 2015 |
McVeigh TP, Jung SY, Kerin MJ, Salzman DW, Nallur S, Nemec AA, Dookwah M, Sadofsky J, Paranjape T, Kelly O, Chan E, Miller N, Sweeney KJ, Zelterman D, Sweasy J, ... ... Weidhaas JB, et al. Estrogen withdrawal, increased breast cancer risk and the KRAS-variant. Cell Cycle (Georgetown, Tex.). 14: 2091-9. PMID 25961464 DOI: 10.1080/15384101.2015.1041694 |
0.787 |
|
| 2015 |
Chen X, Paranjape T, Stahlhut C, McVeigh T, Keane F, Nallur S, Miller N, Kerin M, Deng Y, Yao X, Zhao H, Weidhaas JB, Slack FJ. Targeted resequencing of the microRNAome and 3'UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancer. Oncogene. 34: 2125-37. PMID 24909162 DOI: 10.1038/Onc.2014.117 |
0.608 |
|
| 2015 |
Weidhaas JB, McVeigh TP, Jung SY, Salzman D, Nallur S, Dookwah M, Nemec AA, Sadofsky J, Paranjape T, Kelly O, Chan E, Miller N, Sweeney KJ, Zelterman D, Sweasy J, et al. Estrogen withdrawal, breast cell transformation, and multiple breast cancer risk in women with the KRAS-variant. Journal of Clinical Oncology. 33: e12541-e12541. DOI: 10.1200/Jco.2015.33.15_Suppl.E12541 |
0.772 |
|
| 2015 |
Weidhaas JB, Mcveigh T, Pilarski R, Miller N, Sweasy J, Kerin M, Nallur S, Sadofsky J, Nemec A, Sweeney K, Daniel Z. Abstract P6-10-02: The KRAS-variant, multiple breast cancer risk, and estrogen withdrawal Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P6-10-02 |
0.37 |
|
| 2014 |
Saridaki Z, Weidhaas JB, Lenz HJ, Laurent-Puig P, Jacobs B, De Schutter J, De Roock W, Salzman DW, Zhang W, Yang D, Pilati C, Bouché O, Piessevaux H, Tejpar S. A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4499-510. PMID 25183481 DOI: 10.1158/1078-0432.CCR-14-0348 |
0.769 |
|
| 2014 |
Dorairaj JJ, Salzman DW, Wall D, Rounds T, Preskill C, Sullivan CA, Lindner R, Curran C, Lezon-Geyda K, McVeigh T, Harris L, Newell J, Kerin MJ, Wood M, Miller N, ... Weidhaas JB, et al. A germline mutation in the BRCA1 3'UTR predicts Stage IV breast cancer. Bmc Cancer. 14: 421. PMID 24915755 DOI: 10.1186/1471-2407-14-421 |
0.775 |
|
| 2014 |
Lee LJ, Ratner E, Uduman M, Winter K, Boeke M, Greven KM, King S, Burke TW, Underhill K, Kim H, Boulware RJ, Yu H, Parkash V, Lu L, Gaffney D, ... ... Weidhaas J, et al. The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905. Plos One. 9: e94167. PMID 24732316 DOI: 10.1371/Journal.Pone.0094167 |
0.422 |
|
| 2014 |
Kim M, Chen X, Chin LJ, Paranjape T, Speed WC, Kidd KK, Zhao H, Weidhaas JB, Slack FJ. Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases. Cell Cycle (Georgetown, Tex.). 13: 1030-40. PMID 24552817 DOI: 10.4161/Cc.27941 |
0.656 |
|
| 2014 |
Weidhaas JB, Kim ES, Herbst RS, Yu J, Slack F, Blumenschein GR, Tsao AS, Wistuba II, Lee JJ, Papadimitrakopoulou V, Hong WK, Heymach J, Tran HT. The KRAS-variant and treatment response in BATTLE-1. Journal of Clinical Oncology. 32: 8135-8135. DOI: 10.1200/Jco.2014.32.15_Suppl.8135 |
0.537 |
|
| 2014 |
Weidhaas JB, Harris J, Axelrod R, El-Naggar AK, Singh A, Galloway T, Raben D, Wang D, Herman TS, Lee RJ, Manon RR, Yumen O, Zhang Q, Chung CH. The KRAS-variant and cetuximab response in RTOG 0522. Journal of Clinical Oncology. 32: 6000-6000. DOI: 10.1200/Jco.2014.32.15_Suppl.6000 |
0.393 |
|
| 2013 |
Preskill C, Weidhaas JB. SNPs in microRNA binding sites as prognostic and predictive cancer biomarkers. Critical Reviews in Oncogenesis. 18: 327-40. PMID 23614619 DOI: 10.1615/critrevoncog.2013007254 |
0.435 |
|
| 2013 |
Salzman DW, Weidhaas JB. SNPing cancer in the bud: microRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancer. Pharmacology & Therapeutics. 137: 55-63. PMID 22964086 DOI: 10.1016/j.pharmthera.2012.08.016 |
0.783 |
|
| 2013 |
Howard JD, Cheng H, Ratner E, Fertig EJ, Perez J, Quon H, Considine M, Ochs M, Weidhaas J, Chung CH. Abstract 3100: MicroRNA profiling reveals miR-205 upregulation is associated with head and neck squamous cell carcinoma and modulates E2F1 signaling. Cancer Research. 73: 3100-3100. DOI: 10.1158/1538-7445.Am2013-3100 |
0.306 |
|
| 2012 |
Babar IA, Cheng CJ, Booth CJ, Liang X, Weidhaas JB, Saltzman WM, Slack FJ. Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proceedings of the National Academy of Sciences of the United States of America. 109: E1695-704. PMID 22685206 DOI: 10.1073/Pnas.1201516109 |
0.512 |
|
| 2012 |
Pilarski R, Patel DA, Weitzel J, McVeigh T, Dorairaj JJ, Heneghan HM, Miller N, Weidhaas JB, Kerin MJ, McKenna M, Wu X, Hildebrandt M, Zelterman D, Sand S, Shulman LP. The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer. Plos One. 7: e37891. PMID 22662244 DOI: 10.1371/Journal.Pone.0037891 |
0.384 |
|
| 2012 |
Kundu ST, Nallur S, Paranjape T, Boeke M, Weidhaas JB, Slack FJ. KRAS alleles: the LCS6 3'UTR variant and KRAS coding sequence mutations in the NCI-60 panel. Cell Cycle (Georgetown, Tex.). 11: 361-6. PMID 22189714 DOI: 10.4161/Cc.11.2.18794 |
0.66 |
|
| 2012 |
Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, ... ... Weidhaas JB, et al. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene. 31: 4559-66. PMID 22139083 DOI: 10.1038/Onc.2011.539 |
0.626 |
|
| 2012 |
Kunos C, Winter K, Dicker A, Small W, Abdul-Karim F, Dawson D, Jhingran A, Valicenti R, Weidhaas J, Gaffney D. RTOG 0116 and 0128: Secondary analysis of ribonucleotide reductase in cervix cancer Gynecologic Oncology. 125. DOI: 10.1016/J.Ygyno.2011.12.104 |
0.311 |
|
| 2011 |
Babar IA, Czochor J, Steinmetz A, Weidhaas JB, Glazer PM, Slack FJ. Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells. Cancer Biology & Therapy. 12: 908-14. PMID 22027557 DOI: 10.4161/Cbt.12.10.17681 |
0.555 |
|
| 2011 |
Weidhaas JB, Slack FJ. KRAS rs61764370 in Epithelial Ovarian Cancer-Letter. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6600; author reply 6. PMID 22003074 DOI: 10.1158/1078-0432.Ccr-11-1195 |
0.57 |
|
| 2011 |
Smits KM, Paranjape T, Nallur S, Wouters KA, Weijenberg MP, Schouten LJ, van den Brandt PA, Bosman FT, Weidhaas JB, van Engeland M. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 7723-31. PMID 21994416 DOI: 10.1158/1078-0432.CCR-11-0990 |
0.303 |
|
| 2011 |
Salzman DW, Weidhaas JB. miRNAs in the spotlight: Making 'silent' mutations speak up. Nature Medicine. 17: 934-5. PMID 21818091 DOI: 10.1038/nm0811-934 |
0.75 |
|
| 2011 |
Leaderer D, Hoffman AE, Zheng T, Fu A, Weidhaas J, Paranjape T, Zhu Y. Genetic and epigenetic association studies suggest a role of microRNA biogenesis gene exportin-5 (XPO5) in breast tumorigenesis. International Journal of Molecular Epidemiology and Genetics. 2: 9-18. PMID 21552306 |
0.417 |
|
| 2011 |
Chan E, Patel R, Nallur S, Ratner E, Bacchiocchi A, Hoyt K, Szpakowski S, Godshalk S, Ariyan S, Sznol M, Halaban R, Krauthammer M, Tuck D, Slack FJ, Weidhaas JB. MicroRNA signatures differentiate melanoma subtypes. Cell Cycle (Georgetown, Tex.). 10: 1845-52. PMID 21543894 DOI: 10.4161/Cc.10.11.15777 |
0.588 |
|
| 2011 |
Paranjape T, Heneghan H, Lindner R, Keane FK, Hoffman A, Hollestelle A, Dorairaj J, Geyda K, Pelletier C, Nallur S, Martens JW, Hooning MJ, Kerin M, Zelterman D, Zhu Y, ... ... Weidhaas J, et al. A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. The Lancet. Oncology. 12: 377-86. PMID 21435948 DOI: 10.1016/S1470-2045(11)70044-4 |
0.648 |
|
| 2011 |
Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D, Weidhaas JB, Bader AG, Slack FJ. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 1116-22. PMID 21427705 DOI: 10.1038/Mt.2011.48 |
0.584 |
|
| 2011 |
Chan E, Prado DE, Weidhaas JB. Cancer microRNAs: from subtype profiling to predictors of response to therapy. Trends in Molecular Medicine. 17: 235-43. PMID 21354374 DOI: 10.1016/j.molmed.2011.01.008 |
0.41 |
|
| 2011 |
Pelletier C, Speed WC, Paranjape T, Keane K, Blitzblau R, Hollestelle A, Safavi K, van den Ouweland A, Zelterman D, Slack FJ, Kidd KK, Weidhaas JB. Rare BRCA1 haplotypes including 3'UTR SNPs associated with breast cancer risk. Cell Cycle (Georgetown, Tex.). 10: 90-9. PMID 21191178 DOI: 10.4161/Cc.10.1.14359 |
0.623 |
|
| 2011 |
Godshalk SE, Paranjape T, Nallur S, Speed W, Chan E, Molinaro AM, Bacchiocchi A, Hoyt K, Tworkoski K, Stern DF, Sznol M, Ariyan S, Lazova R, Halaban R, Kidd KK, ... Weidhaas JB, et al. A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanoma. Oncogene. 30: 1542-50. PMID 21119596 DOI: 10.1038/Onc.2010.536 |
0.605 |
|
| 2011 |
Hollestelle A, Pelletier C, Hooning M, Crepin E, Schutte M, Look M, Collee JM, Nieuwlaat A, Dorssers LC, Seynaeve C, Aulchenko YS, Martens JW, van den Ouweland AM, Weidhaas JB. Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families. Breast Cancer Research and Treatment. 128: 79-84. PMID 20676756 DOI: 10.1007/S10549-010-1080-Z |
0.377 |
|
| 2011 |
Weidhaas J, Slack F, Miller N, Harris L, Tuck D, Zhu Y, Zelterman D, Kerin M, Paranjape T, Heneghan H, Lindner R, Keane F, Dorairaj J, Geyda K, Pelletier C, et al. Association between KRAS rs61764370 and triple-negative breast cancer-a false positive? - Authors' reply The Lancet Oncology. 12: 724. DOI: 10.1016/S1470-2045(11)70163-2 |
0.554 |
|
| 2011 |
Ratner E, Keane F, Yu H, Zelterman D, Rutherford T, Santin A, Schwartz P, Slack F, Levine D, Weidhaas J. A 3′ UTR KRAS variant as a biomarker of poor outcome and chemotherapy resistance in ovarian cancer (Gynecologic Oncology (2011) 120, (S3)) Gynecologic Oncology. 122: 205. DOI: 10.1016/J.Ygyno.2011.03.028 |
0.539 |
|
| 2011 |
Ratner E, Keane F, Yu H, Zelterman D, Rutherford T, Santin A, Schwartz P, Slack F, Levine D, Weidhaas J. RETRACTED: A 3’ UTR KRAS variant as a biomarker of poor outcome and chemotherapy resistance in ovarian cancer Gynecologic Oncology. 120: S3. DOI: 10.1016/J.Ygyno.2010.12.010 |
0.516 |
|
| 2010 |
Blitzblau RC, Weidhaas JB. MicroRNA binding-site polymorphisms as potential biomarkers of cancer risk. Molecular Diagnosis & Therapy. 14: 335-42. PMID 21275451 DOI: 10.1007/BF03256390 |
0.432 |
|
| 2010 |
Pelletier C, Weidhaas JB. MicroRNA binding site polymorphisms as biomarkers of cancer risk. Expert Review of Molecular Diagnostics. 10: 817-29. PMID 20843204 DOI: 10.1586/Erm.10.59 |
0.415 |
|
| 2010 |
Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, ... ... Weidhaas JB, et al. A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Research. 70: 6509-15. PMID 20647319 DOI: 10.1158/0008-5472.Can-10-0689 |
0.624 |
|
| 2010 |
Ratner ES, Tuck D, Richter C, Nallur S, Patel RM, Schultz V, Hui P, Schwartz PE, Rutherford TJ, Weidhaas JB. MicroRNA signatures differentiate uterine cancer tumor subtypes. Gynecologic Oncology. 118: 251-7. PMID 20542546 DOI: 10.1016/j.ygyno.2010.05.010 |
0.352 |
|
| 2010 |
Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M, Homer R, Brown D, Bader AG, Weidhaas JB, Slack FJ. Regression of murine lung tumors by the let-7 microRNA. Oncogene. 29: 1580-7. PMID 19966857 DOI: 10.1038/Onc.2009.445 |
0.581 |
|
| 2010 |
Weidhaas JB. A KRAS-variant as a biomarker of ovarian cancer risk. Journal of Clinical Oncology. 28: 5016-5016. DOI: 10.1200/JCO.2010.28.15_SUPPL.5016 |
0.337 |
|
| 2010 |
Paranjape TS, Heneghan H, Pelletier C, Hoffman A, Kerin MJ, Harris L, Zhu Y, Miller N, Zelterman D, Tuck D, Slack F, Weidhaas J. Abstract 3029: A KRAS microRNA binding site polymorphism as a novel biomarker of risk in triple negative breast cancer Cancer Research. 70: 3029-3029. DOI: 10.1158/1538-7445.Am10-3029 |
0.641 |
|
| 2010 |
Weidhaas JB, Slack F. Abstract 1856: A KRAS-variant as a putative biomarker of ovarian cancer risk Cancer Research. 70: 1856-1856. DOI: 10.1158/1538-7445.Am10-1856 |
0.612 |
|
| 2010 |
Heneghan H, Miller N, Paranjape T, Slack F, Weidhaas J, Kerin M. O-43 A KRAS microRNA binding site variant is a genetic marker of risk for triple negative breast cancer European Journal of Cancer Supplements. 8: 16. DOI: 10.1016/J.Ejcsup.2010.06.044 |
0.565 |
|
| 2009 |
Elkin EB, Gonzales AR, Ishill NM, Klem ML, Hodgson D, Ng AK, Marks LB, Weidhaas J, Freedman GM, Miller RC, Yahalom J. Synchronous and metachronous bilateral breast cancer: Are the risks greater in women with a history of radiation for Hodgkin lymphoma? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 607. PMID 27961468 DOI: 10.1200/Jco.2009.27.15_Suppl.607 |
0.329 |
|
| 2009 |
Weidhaas J. Using microRNAs to understand cancer biology. The Lancet. Oncology. 11: 106-7. PMID 20022811 DOI: 10.1016/S1470-2045(09)70386-9 |
0.392 |
|
| 2009 |
Paranjape T, Slack FJ, Weidhaas JB. MicroRNAs: Tools for cancer diagnostics Gut. 58: 1546-1554. PMID 19834118 DOI: 10.1136/Gut.2009.179531 |
0.633 |
|
| 2009 |
Hoffman AE, Zheng T, Yi C, Leaderer D, Weidhaas J, Slack F, Zhang Y, Paranjape T, Zhu Y. microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis. Cancer Research. 69: 5970-7. PMID 19567675 DOI: 10.1158/0008-5472.Can-09-0236 |
0.625 |
|
| 2009 |
Kato M, Paranjape T, Müller RU, Ullrich R, Nallur S, Gillespie E, Keane K, Esquela-Kerscher A, Weidhaas JB, Slack FJ. The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells. Oncogene. 28: 2419-24. PMID 19421141 DOI: 10.1038/Onc.2009.106 |
0.594 |
|
| 2009 |
Paranjape T, Nallur S, Keanie K, Martel M, Haffty B, Tuck D, Slack F, Weidhaas J. MicroRNA profiling of triple negative breast cancer: predicting outcome and targets. Cancer Research. 69: 2040. DOI: 10.1158/0008-5472.Sabcs-2040 |
0.574 |
|
| 2009 |
Kato M, Paranjape T, Müller RU, Nallur S, Gillespie E, Keane K, Esquela-Kerscher A, Weidhaas JB, Slack FJ. Erratum: The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells Oncogene. 28: 3008-3008. DOI: 10.1038/onc.2009.218 |
0.309 |
|
| 2008 |
Trang P, Weidhaas JB, Slack FJ. MicroRNAs as potential cancer therapeutics Oncogene. 27. PMID 19956180 DOI: 10.1038/Onc.2009.353 |
0.623 |
|
| 2008 |
Slack FJ, Weidhaas JB. MicroRNA in cancer prognosis. The New England Journal of Medicine. 359: 2720-2. PMID 19092157 DOI: 10.1056/Nejme0808667 |
0.61 |
|
| 2008 |
Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, Muller RU, Straka E, Su L, Burki EA, Crowell RE, Patel R, Kulkarni T, Homer R, Zelterman D, ... ... Weidhaas JB, et al. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Research. 68: 8535-40. PMID 18922928 DOI: 10.1158/0008-5472.Can-08-2129 |
0.605 |
|
| 2008 |
Babar IA, Slack FJ, Weidhaas JB. miRNA modulation of the cellular stress response. Future Oncology (London, England). 4: 289-98. PMID 18407740 DOI: 10.2217/14796694.4.2.289 |
0.559 |
|
| 2008 |
Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L, Weidhaas JB, Brown D, Bader AG, Slack FJ. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle (Georgetown, Tex.). 7: 759-64. PMID 18344688 DOI: 10.4161/Cc.7.6.5834 |
0.571 |
|
| 2007 |
Weidhaas JB, Babar I, Nallur SM, Trang P, Roush S, Boehm M, Gillespie E, Slack FJ. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Research. 67: 11111-6. PMID 18056433 DOI: 10.1158/0008-5472.Can-07-2858 |
0.619 |
|
| 2007 |
Weidhaas J, Slack F, Babar I, Nallur S. Using MicroRNAs to Alter the Radiation Response International Journal of Radiation Oncology*Biology*Physics. 69: S145-S146. DOI: 10.1016/J.Ijrobp.2007.07.266 |
0.465 |
|
| 2006 |
Slack FJ, Weidhaas JB. MicroRNAs as a potential magic bullet in cancer. Future Oncology (London, England). 2: 73-82. PMID 16556074 DOI: 10.2217/14796694.2.1.73 |
0.643 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2019 |
Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, ... ... Weidhaas JB, et al. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. Journal For Immunotherapy of Cancer. 7: 131. PMID 31113486 DOI: 10.1186/S40425-019-0602-4 |
0.296 |
|
| 2006 |
Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 5652-7. PMID 17116942 DOI: 10.1200/JCO.2006.06.5664 |
0.293 |
|
| 2017 |
Hegde JV, Wang X, Attai DJ, DiNome ML, Kusske A, Hoyt AC, Hurvitz SA, Weidhaas JB, Steinberg ML, McCloskey SA. Assessing the Effect of Lifetime Contralateral Breast Cancer Risk on the Selection of Contralateral Prophylactic Mastectomy for Unilateral Breast Cancer. Clinical Breast Cancer. PMID 29050918 DOI: 10.1016/j.clbc.2017.09.010 |
0.29 |
|
| 2017 |
Hegde JV, Wang X, Attai DJ, DiNome ML, Kusske A, Hoyt AC, Hurvitz SA, Weidhaas JB, Steinberg ML, McCloskey SA. Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer. Breast Cancer Research and Treatment. PMID 28702891 DOI: 10.1007/s10549-017-4392-4 |
0.287 |
|
| 2012 |
Grechukhina O, Petracco R, Popkhadze S, Massasa E, Paranjape T, Chan E, Flores I, Weidhaas JB, Taylor HS. A polymorphism in a let-7 microRNA binding site of KRAS in women with endometriosis. Embo Molecular Medicine. 4: 206-17. PMID 22307873 DOI: 10.1002/emmm.201100200 |
0.276 |
|
| 2013 |
Ahmad A, Ahmad S, Weidhaas J, Hui P, Santin A, Azodi M, Silasi D, Schwartz P, Rutherford T, Ratner E. Ovarian versus uterine serous carcinomas: Clinicopathologic and miRNA analysis Gynecologic Oncology. 130: e92. DOI: 10.1016/J.YGYNO.2013.04.274 |
0.27 |
|
| 2013 |
Moran MS, Ma S, Jagsi R, Yang TJ, Higgins SA, Weidhaas JB, Wilson LD, Lloyd S, Peschel R, Gaudreau B, Rockwell S. A prospective, multicenter study of complementary/alternative medicine (CAM) utilization during definitive radiation for breast cancer. International Journal of Radiation Oncology, Biology, Physics. 85: 40-6. PMID 22658441 DOI: 10.1016/J.Ijrobp.2012.03.025 |
0.27 |
|
| 2009 |
Christy CJ, Thorsteinsson D, Grube BJ, Black D, Abu-Khalaf M, Chung GG, DiGiovanna MP, Miller K, Higgins SA, Weidhaas J, Harris L, Tavassoli FA, Lannin DR. Preoperative chemotherapy decreases the need for re-excision of breast cancers between 2 and 4 cm diameter. Annals of Surgical Oncology. 16: 697-702. PMID 19132447 DOI: 10.1245/s10434-008-0268-5 |
0.267 |
|
| 2022 |
Weidhaas J, Marco N, Scheffler AW, Kalbasi A, Wilenius K, Rietdorf E, Gill J, Heilig M, Desler C, Chin RK, Kaprealian T, McCloskey S, Raldow A, Raja NP, Kesari S, et al. Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy. Journal For Immunotherapy of Cancer. 10. PMID 35115362 DOI: 10.1136/jitc-2021-003625 |
0.266 |
|
| 2022 |
Kishan AU, Marco N, Schulz-Jaavall MB, Steinberg ML, Tran PT, Juarez JE, Dang A, Telesca D, Lilleby WA, Weidhaas JB. Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 34990726 DOI: 10.1016/j.radonc.2021.12.040 |
0.26 |
|
| 2016 |
Weidhaas J, Harris J, Schaue D, Chen A, Chin R, Axelrod R, El-Naggar A, Singh A, Galloway T, Raben D, Wang D, Matthiesen C, Avizonis V, Manon R, Yumen O, et al. The KRAS-variant is a Biomarker of Cetuximab Response and Altered Immunity in Head and Neck Cancer: NRG Oncology/RTOG 0522 International Journal of Radiation Oncology*Biology*Physics. 96: 941-942. DOI: 10.1016/j.ijrobp.2016.09.055 |
0.258 |
|
| 2014 |
Gaffney DK, Jhingran A, Portelance L, Viswanathan A, Schefter T, Weidhaas J, Small W. Radiation therapy oncology group gynecologic oncology working group: comprehensive results. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 24: 956-62. PMID 24819663 DOI: 10.1097/IGC.0000000000000135 |
0.256 |
|
| 2023 |
Weidhaas JB, Hu C, Komaki R, Masters GA, Blumenschein GR, Chang JY, Lu B, Dicker AP, Bogart JA, Garces YI, Narayan S, Robinson CG, Kavadi VS, Greenberger JS, Koprowski CD, et al. The inherited KRAS-variant as a biomarker of Cetuximab Response in NSCLC. Cancer Research Communications. PMID 37728512 DOI: 10.1158/2767-9764.CRC-23-0084 |
0.255 |
|
| 2011 |
Elkin EB, Klem ML, Gonzales AM, Ishill NM, Hodgson D, Ng AK, Marks LB, Weidhaas J, Freedman GM, Miller RC, Constine LS, Myrehaug S, Yahalom J. Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin's lymphoma: a multi-institutional, matched cohort study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2466-73. PMID 21576642 DOI: 10.1200/Jco.2010.32.4079 |
0.254 |
|
| 2011 |
Weidhaas J. Biologic profiling of lymph node negative breast cancers by means of microRNA expression Breast Diseases: a Year Book Quarterly. 22: 276. DOI: 10.1016/J.BREASTDIS.2011.06.025 |
0.246 |
|
| 2015 |
McVeigh TP, Owens PW, Mulligan R, Miller N, Guerin C, Sebag F, Quill D, Bell M, Lowery AJ, Weidhaas JB, Kerin MJ. 22. Investigating the role of polymorphism rs2910164 in mir146a in cancer predisposition European Journal of Surgical Oncology (Ejso). 41: S85-S86. DOI: 10.1016/J.EJSO.2015.08.098 |
0.246 |
|
| 2010 |
Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, Weidhaas J, Paik D, Van Den Berg DJ, Stram DO, Pearce CL, et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nature Genetics. 42: 880-4. PMID 20852633 DOI: 10.1038/Ng.666 |
0.243 |
|
| 2009 |
Weidhaas JB, Li SX, Winter K, Ryu J, Jhingran A, Miller B, Dicker AP, Gaffney D. Changes in gene expression predicting local control in cervical cancer: results from Radiation Therapy Oncology Group 0128. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4199-206. PMID 19509178 DOI: 10.1158/1078-0432.CCR-08-2257 |
0.235 |
|
| 2011 |
Moran MS, Yang J, Ma S, Gaudreau B, Higgins SA, Weidhaas JB, Wilson LD, Peschel R, Fass D, Rockwell S. A prospective, multicenter trial of complementary and alternative medicine (CAM) utilization by patients undergoing definitive breast radiotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 241. PMID 27958065 DOI: 10.1200/jco.2011.29.27_suppl.241 |
0.226 |
|
| 2008 |
Doll C, Winter K, Gaffney D, Ryu J, Jhingran A, Dicker A, Weidhaas J, Miller B, Magliocco A. ERCC1, COX-2, and p53 Expression in Patients with Locally Advanced Cervical Cancer Treated with Chemoradiotherapy and Celecoxib: A Quantitative Immunohistochemical Analysis of RTOG 0128 International Journal of Radiation Oncology*Biology*Physics. 72: S355-S356. DOI: 10.1016/J.IJROBP.2008.06.1180 |
0.223 |
|
| 2008 |
Weidhaas JB, Li S, Winter K, Ryu J, Jhingra A, Miller B, Dicker A, Gaffney D. Changes in Gene Expression Predicting Local Control in Cervical Cancer: Results from RTOG 0128 International Journal of Radiation Oncology Biology Physics. 72. DOI: 10.1016/J.Ijrobp.2008.06.802 |
0.219 |
|
| 2013 |
Weidhaas JB, Lee J, Slebos R, Howard J, Perez J, Gilbert J, Nallur S, Paranjape T, Garcia JJ, Burtness B, Forastiere AA, Chung CH. Association of the 3'-untranslated region KRAS-variant with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Journal of Clinical Oncology. 31: 6016-6016. DOI: 10.1200/JCO.2013.31.15_SUPPL.6016 |
0.218 |
|
| 2022 |
Orozco JIJ, Le J, Ensenyat-Mendez M, Baker JL, Weidhaas J, Klomhaus A, Marzese DM, DiNome ML. Machine Learning-Based Epigenetic Classifiers for Axillary Staging of Patients with ER-Positive Early-Stage Breast Cancer. Annals of Surgical Oncology. PMID 35842534 DOI: 10.1245/s10434-022-12143-6 |
0.21 |
|
| 2022 |
Ensenyat-Mendez M, Rünger D, Orozco JIJ, Le J, Baker JL, Weidhaas J, Marzese DM, DiNome ML. ASO Visual Abstract: Epigenetic Signatures Predict Pathologic Nodal Stage in Breast Cancer Patients with Estrogen-Receptor-Positive, Clinically Node-Positive Disease. Annals of Surgical Oncology. PMID 35430657 DOI: 10.1245/s10434-022-11744-5 |
0.208 |
|
| 2014 |
Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, Nallur S, Paranjape T, Jordan RC, Garcia J, Burtness B, ... ... Weidhaas JB, et al. A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 25: 2230-6. PMID 25081901 DOI: 10.1093/Annonc/Mdu367 |
0.206 |
|
| 2009 |
Doll C, Winter K, Gaffney D, Ryu J, Jhingran A, Dicker A, Weidhaas J, Miller B, Diaz R, Magliocco A. Low COX-2 Expression, But Not CD34, Predicts for Worse Overall Survival in Patients with Locally-advanced Cervical Cancer Treated with Chemoradiotherapy and Celecoxib: A Comparative Immunohistochemical Analysis of RTOG 0128 International Journal of Radiation Oncology*Biology*Physics. 75: S150-S151. DOI: 10.1016/J.IJROBP.2009.07.355 |
0.199 |
|
| 2015 |
Chen J, Morrical MD, Donigan KA, Weidhaas JB, Sweasy JB, Averill AM, Tomczak JA, Morrical SW. Tumor-associated mutations in a conserved structural motif alter physical and biochemical properties of human RAD51 recombinase. Nucleic Acids Research. 43: 1098-111. PMID 25539919 DOI: 10.1093/Nar/Gku1337 |
0.198 |
|
| 2019 |
Kishan A, Romero T, Grogan T, Alshalalfa M, Boutros P, Rettig M, Reiter R, Tran P, Nguyen P, Nickols N, Davicioni E, Spratt D, Feng F, Den R, Freedland S, ... ... Weidhaas J, et al. Transcriptomic Heterogeneity in Pathological Grade Group 5 Prostate Cancer: Implications for Biomarker Discovery International Journal of Radiation Oncology*Biology*Physics. 105: E286-E287. DOI: 10.1016/J.Ijrobp.2019.06.1823 |
0.196 |
|
| 2019 |
Rahimy E, Weidhaas J, Wei W, Lannin D, Horowitz N, Higgins S, Wilson LD, Knowlton C, Moran MS, Young MR, Killelea B, Chagpar A, Yeboa DN, Zelterman D, Evans S. Patient Reported Outcomes and Cosmesis in a Feasibility Study of 4D Simulated Image Guided Accelerated Partial Breast Irradiation (APBI). Practical Radiation Oncology. PMID 30796975 DOI: 10.1016/J.Prro.2019.01.013 |
0.196 |
|
| 2015 |
Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, Weidhaas J, Paik D, Van Den Berg DJ, Stram DO, Pearce CL, et al. Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nature Genetics. 48: 101. PMID 26711112 DOI: 10.1038/Ng0116-101B |
0.191 |
|
| 2020 |
Kishan AU, Romero T, Alshalalfa M, Liu Y, Tran PT, Nickols NG, Ye H, Sajed D, Rettig MB, Reiter RE, Garraway IP, Spratt DE, Freedland SJ, Zhao X, Li Z, ... ... Weidhaas JB, et al. Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. European Urology. PMID 32461072 DOI: 10.1016/J.Eururo.2020.05.009 |
0.19 |
|
| 2020 |
Jia Y, McKenzie E, Sheng K, Ruan D, Weidhaas J, Raldow A, Qi X. Prediction of Post-chemoradiotherapy Response for Patients with Local Advanced Rectal Cancer Using Pre-treatment CT and PET Radiomics International Journal of Radiation Oncology*Biology*Physics. 108: S31-S32. DOI: 10.1016/j.ijrobp.2020.07.2129 |
0.188 |
|
| 2018 |
Higa J, Wilenius K, Weidhaas JB, Larsen C, Lam RY, Turner J, Scholz MC. Pembrolizumab for recurrent or advanced prostate cancer. Journal of Clinical Oncology. 36: 250-250. DOI: 10.1200/Jco.2018.36.6_Suppl.250 |
0.185 |
|
| 2020 |
Valle L, Ruan D, Dang A, Levin-Epstein R, Patel A, Weidhaas J, Nickols N, Lee P, Low D, Qi S, King C, Steinberg M, Kupelian P, Cao M, Kishan A. Development and Validation of a Comprehensive Multivariate Dosimetric Model for Predicting Late Genitourinary Toxicity Following Prostate Cancer Stereotactic Body Radiotherapy International Journal of Radiation Oncology Biology Physics. 108. DOI: 10.1016/J.Ijrobp.2020.02.626 |
0.184 |
|
| 2016 |
Weidhaas JB, Harris J, Schaue D, Chen AM, Chin R, Axelrod R, El-Naggar AK, Singh AK, Galloway TJ, Raben D, Wang D, Matthiesen C, Avizonis VN, Manon RR, Yumen O, et al. The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial. Jama Oncology. PMID 28006059 DOI: 10.1001/Jamaoncol.2016.5478 |
0.182 |
|
| 2019 |
Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, ... ... Weidhaas JB, et al. Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. Journal For Immunotherapy of Cancer. 7: 167. PMID 31272507 DOI: 10.1186/S40425-019-0640-Y |
0.182 |
|
| 2022 |
Orozco JIJ, Le J, Ensenyat-Mendez M, Baker JL, Weidhaas J, Klomhaus A, Marzese DM, DiNome ML. ASO Visual Abstract: Machine Learning-Based Epigenetic Classifiers for Axillary Staging of Patients with ER-Positive Early-Stage Breast Cancer. Annals of Surgical Oncology. PMID 35849286 DOI: 10.1245/s10434-022-12245-1 |
0.182 |
|
| 2019 |
D'Hooghe TM, Grechukhina O, Cho S, Fassbender A, O D, Peterse D, Weidhaas J, Taylor HS. Lack of an Association between a Polymorphism in the KRAS 3' Untranslated Region (rs61764370) and Endometriosis in a Large European Case-Control Study. Gynecologic and Obstetric Investigation. 1-8. PMID 31185482 DOI: 10.1159/000500626 |
0.181 |
|
| 2019 |
Kishan AU, Romero T, Elashoff D, Grogan T, Rettig M, Reiter RE, Tran PT, Nguyen PL, Nickols NG, Davicioni E, Spratt DE, Feng FY, Weidhaas JB. Genomic biomarkers to predict outcome in Gleason Score 9-10 disease. Journal of Clinical Oncology. 37: 44-44. DOI: 10.1200/Jco.2019.37.7_Suppl.44 |
0.175 |
|
| 2020 |
Weidhaas JB, Telesca D, Kishan AU, Guldvik IJ, Schulz-Jaavall M, Stensvold A, Tran PT, Lilleby W. MicroRNA-based biomarkers of the radiation response in prostate cancer. Journal of Clinical Oncology. 38: 163-163. DOI: 10.1200/Jco.2020.38.6_Suppl.163 |
0.173 |
|
| 2018 |
Shaverdian N, Wang X, Hegde JV, Aledia C, Weidhaas JB, Steinberg ML, McCloskey SA. The patient's perspective on breast radiotherapy: Initial fears and expectations versus reality. Cancer. PMID 29479673 DOI: 10.1002/cncr.31159 |
0.172 |
|
| 2023 |
Li Z, Raldow AC, Weidhaas JB, Zhou Q, Qi XS. Prediction of Radiation Treatment Response for Locally Advanced Rectal Cancer via a Longitudinal Trend Analysis Framework on Cone-Beam CT. Cancers. 15. PMID 37958316 DOI: 10.3390/cancers15215142 |
0.171 |
|
| 2013 |
Kunos CA, Winter K, Dicker AP, Small W, Abdul-Karim FW, Dawson D, Jhingran A, Valicenti R, Weidhaas JB, Gaffney DK. Ribonucleotide reductase expression in cervical cancer: a radiation therapy oncology group translational science analysis. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 23: 615-21. PMID 23552804 DOI: 10.1097/Igc.0B013E31828B4Eb5 |
0.17 |
|
| 2020 |
Valle LF, Ruan D, Dang A, Levin-Epstein RG, Patel AP, Weidhaas JB, Nickols NG, Lee PP, Low DA, Qi XS, King CR, Steinberg ML, Kupelian PA, Cao M, Kishan AU. Development and Validation of a Comprehensive Multivariate Dosimetric Model for Predicting Late Genitourinary Toxicity Following Prostate Cancer Stereotactic Body Radiotherapy. Frontiers in Oncology. 10: 786. PMID 32509582 DOI: 10.3389/Fonc.2020.00786 |
0.168 |
|
| 2013 |
Doll CM, Winter K, Gaffney DK, Ryu JK, Jhingran A, Dicker AP, Weidhaas JB, Miller BE, Magliocco AM. COX-2 expression and survival in patients with locally advanced cervical cancer treated with chemoradiotherapy and celecoxib: a quantitative immunohistochemical analysis of RTOG C0128. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 23: 176-83. PMID 23221733 DOI: 10.1097/IGC.0b013e3182791efc |
0.164 |
|
| 2008 |
Yu JB, Wilson LD, Dasgupta T, Castrucci WA, Weidhaas JB. Postmastectomy radiation therapy for lymph node-negative, locally advanced breast cancer after modified radical mastectomy: analysis of the NCI Surveillance, Epidemiology, and End Results database. Cancer. 113: 38-47. PMID 18442108 DOI: 10.1002/cncr.23512 |
0.162 |
|
| 2011 |
Hansen JE, Reza F, Nallur S, Lewis J, Carlson KR, Lin WM, Weidhaas JB, Wilson LD, Girardi M. MicroRNA Profiling of Cutaneous T-cell Lymphoma Cell Lines: Implications for Pathophysiology and Therapy International Journal of Radiation Oncology Biology Physics. 81. DOI: 10.1016/J.Ijrobp.2011.06.045 |
0.153 |
|
| 2022 |
Ensenyat-Mendez M, Rünger D, Orozco JIJ, Le J, Baker JL, Weidhaas J, Marzese DM, DiNome ML. Epigenetic Signatures Predict Pathologic Nodal Stage in Breast Cancer Patients with Estrogen Receptor-Positive, Clinically Node-Positive Disease. Annals of Surgical Oncology. PMID 35397740 DOI: 10.1245/s10434-022-11684-0 |
0.151 |
|
| 2008 |
Grube BJ, Christy CJ, Black D, Martel M, Harris L, Weidhaas J, Digiovanna MP, Chung G, Abu-Khalaf MM, Miller KD, Higgins SA, Philpotts L, Tavassoli FA, Lannin DR. Breast sentinel lymph node dissection before preoperative chemotherapy. Archives of Surgery (Chicago, Ill. : 1960). 143: 692-9; discussion 69. PMID 18645113 DOI: 10.1001/archsurg.143.7.692 |
0.149 |
|
| 2006 |
Weidhaas JB, Eisenmann DM, Holub JM, Nallur SV. A conserved RAS/mitogen-activated protein kinase pathway regulates DNA damage-induced cell death postirradiation in Radelegans. Cancer Research. 66: 10434-8. PMID 17079464 DOI: 10.1158/0008-5472.Can-06-2182 |
0.149 |
|
| 2018 |
Yuan Y, Heilig M, Jung S, Rietdorf E, Weidhaas J. MicroRNA-138 Regulation of PD-L1 Expression Immediately after Radiation is Altered by the rs4742098 Variant International Journal of Radiation Oncology*Biology*Physics. 102: S156. DOI: 10.1016/J.IJROBP.2018.06.376 |
0.148 |
|
| 2023 |
Smith CP, Proudfoot JA, Boutros PC, Reiter RE, Valle L, Rettig MB, Nickols NG, Feng FY, Nguyen PL, Nagar H, Spratt DE, Attard G, Weiner A, Weidhaas JB, Calais J, et al. Transcriptomic Heterogeneity in High-risk Prostate Cancer and Implications for Extraprostatic Disease at Presentation on Prostate-specific Membrane Antigen Positron Emission Tomography. European Urology Oncology. PMID 36870853 DOI: 10.1016/j.euo.2023.02.009 |
0.136 |
|
| 2014 |
Nath SK, Chen ZJ, Rowe BP, Blitzblau RC, Aneja S, Grube BJ, Horowitz NR, Weidhaas JB. A PHASE II TRIAL OF BALLOON-CATHETER PARTIAL BREAST BRACHYTHERAPY OPTIMIZATION IN THE TREATMENT OF STAGE 0, I AND IIA BREAST CARCINOMA. Journal of Radiation Oncology. 3: 371-378. PMID 25485042 DOI: 10.1007/s13566-014-0153-8 |
0.136 |
|
| 2019 |
Kishan AU, Ruan D, Dang AT, Chu FI, Steinberg ML, Weidhaas JB. MicroRNA-based Biomarkers predicting Long-Term Toxicity to Prostate SBRT International Journal of Radiation Oncology Biology Physics. 105. DOI: 10.1016/J.Ijrobp.2019.06.459 |
0.132 |
|
| 2010 |
Lee LJ, Winter K, Ratner E, Greven KM, King S, Burke TW, Underhill K, Kim H, Boulware RJ, Weidhaas J. The KRAS-variant and Outcome in Endometrial Adenocarcinoma: Combined Analysis of RTOG 9708 and 9905 International Journal of Radiation Oncology Biology Physics. 78. DOI: 10.1016/J.Ijrobp.2010.07.946 |
0.124 |
|
| 2012 |
Smits KM, Paranjape T, Nallur S, Wouters KAD, Weijenberg MP, Schouten LJ, Van Den Brandt PA, Bosman FT, Weidhaas JB, Van Engeland M. KRAS-LCS6 genotype as a prognostic marker in early-stage CRC-response Clinical Cancer Research. 18: 3489. DOI: 10.1158/1078-0432.CCR-12-1023 |
0.12 |
|
| 2006 |
Weidhaas JB, Ponn T, Chen Z, Martel M, Zelterman D. 2052 : A Phase II Trial of Mammosite Breast Brachytherapy Optimization in the Treatment of Stage 0, I and II Breast Carcinoma International Journal of Radiation Oncology Biology Physics. 66. DOI: 10.1016/J.Ijrobp.2006.07.455 |
0.12 |
|
| 2017 |
Hall WA, Bergom C, Thompson RF, Baschnagel AM, Vijayakumar S, Willers H, Li XA, Schultz CJ, Wilson GD, West CML, Capala J, Coleman CN, Torres-Roca JF, Weidhaas J, Feng FY. Precision Oncology and Genomically Guided Radiation Therapy: A Report From the American Society for Radiation Oncology/American Association of Physicists in Medicine/National Cancer Institute Precision Medicine Conference. International Journal of Radiation Oncology, Biology, Physics. PMID 28964588 DOI: 10.1016/J.Ijrobp.2017.05.044 |
0.109 |
|
| 2023 |
Kishan AU, Marco N, Ma TM, Steinberg ML, Sachdeva A, Cao M, Ballas LK, Rietdorf E, Telesca D, Weidhaas JB. Application of a genetic signature of late GU toxicity in SCIMITAR, a Post-op SBRT trial. Clinical and Translational Radiation Oncology. 39: 100594. PMID 36880064 DOI: 10.1016/j.ctro.2023.100594 |
0.109 |
|
| 2013 |
Nath S, Chen Z, Rowe B, Blitzblau R, Aneja S, Grube B, Horowitz N, Weidhaas J. Using Skin Dose Parameters Predicts Low Skin Toxicity in a Phase 2 Trial of Multiple Dwell Position Balloon-Based Brachytherapy for Partial Breast Irradiation International Journal of Radiation Oncology*Biology*Physics. 87: S213. DOI: 10.1016/J.IJROBP.2013.06.551 |
0.107 |
|
| 2020 |
Kalbasi A, Kamrava M, Chu FI, Telesca D, Van Dams R, Yang Y, Ruan D, Nelson SD, Dry S, Hernandez J, Chmielowski B, Singh AS, Bukata SV, Bernthal N, Steinberg ML, ... Weidhaas JB, et al. A Phase 2 Trial of Five-Day Neoadjuvant Radiation Therapy for Patients with High-Risk Primary Soft Tissue Sarcoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32054730 DOI: 10.1158/1078-0432.Ccr-19-3524 |
0.102 |
|
| 2023 |
Ma TM, Wong DJ, Chai-Ho W, Mendelsohn A, John MS, Abemayor E, Chhetri D, Sajed D, Dang A, Chu FI, Xiang M, Savjanji R, Weidhaas J, Steinberg ML, Cao M, et al. High Recurrence For HPV-Positive Oropharyngeal Cancer With Neoadjuvant Radiotherapy To Gross Disease Plus Immunotherapy: Analysis From a Prospective Phase Ib/II Clinical Trial. International Journal of Radiation Oncology, Biology, Physics. PMID 37141981 DOI: 10.1016/j.ijrobp.2023.04.029 |
0.1 |
|
| 2014 |
Wallner PE, Anscher MS, Barker CA, Bassetti M, Bristow RG, Cha YI, Dicker AP, Formenti SC, Graves EE, Hahn SM, Hei TK, Kimmelman AC, Kirsch DG, Kozak KR, Lawrence TS, ... ... Weidhaas JB, et al. Current status and recommendations for the future of research, teaching, and testing in the biological sciences of radiation oncology: report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force, executive summary. International Journal of Radiation Oncology, Biology, Physics. 88: 11-7. PMID 24246724 DOI: 10.1016/J.Ijrobp.2013.09.040 |
0.097 |
|
| 2006 |
Weidhaas JB, Eisenmann DM, Holub JM, Nallur SV. A Caenorhabditis elegans tissue model of radiation-induced reproductive cell death Proceedings of the National Academy of Sciences of the United States of America. 103: 9946-9951. PMID 16788064 DOI: 10.1073/Pnas.0603791103 |
0.091 |
|
| 2003 |
Weidhaas J, Holub J, Leibel S, Fuks Z, Eisenmann D, Kolesnick R. An in vivo tissue-model of mitotic cell death and EGFR-signaling International Journal of Radiation Oncology*Biology*Physics. 57: S293. DOI: 10.1016/S0360-3016(03)01151-9 |
0.061 |
|
| 2017 |
Mufson J, Handorf E, Weidhaas J, Lango M, Burtness B, Golemis E, Ridge JA, Mehra R. Abstract 4732: Analysis of KRAS variant in a cohort of resected HPV negative HNSCC Cancer Research. 77: 4732-4732. DOI: 10.1158/1538-7445.Am2017-4732 |
0.053 |
|
| 2022 |
Gunatilaka AB, Marco N, Read GH, Sweeney M, Regan G, Tsang C, Abdulrahman L, Ampabathina S, Spindler A, Lu SS, Schink E, Gatti R, Ingersoll C, Telesca D, Weidhaas JB. Viral Burden and Clearance in Asymptomatic COVID-19 Patients. Open Forum Infectious Diseases. 9: ofac126. PMID 35493121 DOI: 10.1093/ofid/ofac126 |
0.042 |
|
| 2011 |
Weidhaas JB, Kirsch DG. The Holman Research Pathway in radiation oncology. International Journal of Radiation Oncology, Biology, Physics. 80: 321-3. PMID 21549248 DOI: 10.1016/j.ijrobp.2011.01.030 |
0.041 |
|
| 2000 |
Weidhaas JB, Angelichio EL, Fenner S, Coffin JM. Relationship between retroviral DNA integration and gene expression. Journal of Virology. 74: 8382-9. PMID 10954538 DOI: 10.1128/JVI.74.18.8382-8389.2000 |
0.034 |
|
| 2010 |
Rowe B, Blitzblau R, Chen Z, Grube B, Weidhaas J. Reduced Skin Toxicity with Multiple Dwell Position Mammosite Brachytherapy: Preliminary Phase II Trial Results International Journal of Radiation Oncology*Biology*Physics. 78: S246. DOI: 10.1016/J.IJROBP.2010.07.588 |
0.032 |
|
| 2008 |
Blitzblau R, Chen Z, Grube B, Weidhaas J. Multidwell Position MammoSite Brachytherapy Decreases Skin Toxicity, Preliminary Results of a Phase II Trial International Journal of Radiation Oncology*Biology*Physics. 72: S186. DOI: 10.1016/J.IJROBP.2008.06.757 |
0.029 |
|
| 2006 |
Ahmad M, Song H, Lund M, Niemierko A, Moran M, Weidhaas J, Higgins S, Chen Z, Deng J, Nath R. SU-FF-T-361: Planning Study of Intensity-Modulated and 3D Conformal Radiotherapy of Whole Pelvis Including Inguinal Lymphatics: Radiobiological Considerations for Designing New Fractionation Schemes Medical Physics. 33: 2129-2129. DOI: 10.1118/1.2241281 |
0.025 |
|
| 2019 |
Vapiwala N, Thomas CR, Grover S, Yap ML, Mitin T, Shulman LN, Gospodarowicz MK, Longo J, Petereit DG, Ennis RD, Hayman JA, Rodin D, Buchsbaum JC, Vikram B, Abdel-Wahab M, ... ... Weidhaas JB, et al. Enhancing Career Paths for Tomorrow's Radiation Oncologists. International Journal of Radiation Oncology, Biology, Physics. PMID 31128144 DOI: 10.1016/J.Ijrobp.2019.05.025 |
0.021 |
|
| Hide low-probability matches. |